Modeling how the immune system reacts to transplanted organs using advanced technology.
Vascularized liver-heart on-a-chip modeling antibody-mediated rejection and tolerance of allografts
This study is looking at how the immune system reacts to transplanted organs, like the liver and heart, to find out which antibodies might cause rejection, with the hope of helping transplant patients have better outcomes and less need for long-term medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Terasaki Institute for Biomedical Innovation NIH-funded |
| Lab location | 1 site (Woodland Hills, UNITED STATES) |
| Project ID | NIH-10860820 on NIH RePORTER |
What this research studies
This research focuses on understanding how the immune system responds to transplanted organs, particularly in the context of antibody-mediated rejection. By developing a multi-organ-on-a-chip platform, the study aims to simulate the interactions between the liver and heart to identify specific antibodies that may lead to rejection of transplanted organs. This innovative approach allows researchers to study these complex interactions in a controlled environment, potentially leading to better diagnostic tools and treatment strategies for transplant recipients. Patients may benefit from insights gained through this research, which could improve transplant outcomes and reduce the need for lifelong immunosuppression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received or are considering organ transplants, particularly of the liver or heart.
Not a fit: Patients who are not candidates for organ transplantation or those with conditions unrelated to organ rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing organ rejection in transplant patients.
How similar studies have performed: While organ-on-a-chip technologies are gaining traction, this specific approach to studying antibody-mediated rejection is relatively novel and has not been extensively tested.
Where this research is happening
Woodland Hills, UNITED STATES
- Terasaki Institute for Biomedical Innovation — Woodland Hills, United States (Active)
Researchers
- Principal investigator: Jucaud, Vadim — Terasaki Institute for Biomedical Innovation
- Study coordinator: Jucaud, Vadim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.